Calcitriol, used in treating bone disease in hemodialysis patients, is what kind of medication?

Calcitriol, used in treating bone disease in hemodialysis patients, is what kind of medication?

• A. Phosphate binder
• B. Vitamin D analog
• C. Calcimimetic
• D. Calcium supplement

Answer: (B)

Calcitriol is an active form of vitamin D used to treat bone disease in hemodialysis patients. It works as a vitamin D analog, binding to vitamin D receptors to boost calcium (and phosphate) absorption from the gut and to help suppress parathyroid hormone, which often becomes elevated in kidney disease. This approach directly addresses vitamin D deficiency and secondary hyperparathyroidism that drive bone mineral disorders in CKD. It’s not a phosphate binder (which lowers phosphate by binding it in the gut), not a calcimimetic (which lowers PTH by increasing the calcium-sensing receptor’s activity), and not simply a calcium supplement (which adds calcium without addressing vitamin D action or PTH). In kidney disease, activating vitamin D helps stabilize mineral balance and bone turnover.

Calcitriol is an active form of vitamin D used to treat bone disease in hemodialysis patients. It works as a vitamin D analog, binding to vitamin D receptors to boost calcium (and phosphate) absorption from the gut and to help suppress parathyroid hormone, which often becomes elevated in kidney disease. This approach directly addresses vitamin D deficiency and secondary hyperparathyroidism that drive bone mineral disorders in CKD. It’s not a phosphate binder (which lowers phosphate by binding it in the gut), not a calcimimetic (which lowers PTH by increasing the calcium-sensing receptor’s activity), and not simply a calcium supplement (which adds calcium without addressing vitamin D action or PTH). In kidney disease, activating vitamin D helps stabilize mineral balance and bone turnover.